FDAsafety guidance65% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Regeneron.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Skin Cancer
- Sub-indication
- General
Related signal: Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
Source
FDA document
View source